Acuta Capital Bets on Erasca (ERAS) and Targeted Cancer Treatment for 354,575 Share Buy
What’s going on
According to an SEC filing dated May 15, 2026, Akuta Capital Partners, LLC started a new position Erasca (NASDAQ:ERAS) during the first quarter. The fund acquired 354,575 shares, with an estimated transaction value of $4.19 million based on the average closing price of that period. The stock’s quarter-end value rose to $5.74 million, a change that reflects both the addition of shares and price volatility during the quarter.
Another thing you need to know
-
This was the fund’s new position, representing 4.05% of reported US equities as of March 31, 2026.
-
Top benefits after installation:
-
NASDAQ: PRAX: $27.35 million (19.8% of AUM)
-
NASDAQ: TERN: $26.14 million (18.9% of AUM)
-
NASDAQ: WHWK: $11.77 million (8.5% of AUM)
-
NASDAQ: TNGX: $9.24 million (6.7% of AUM)
-
NASDAQ: IDRUG: $8.17 million (5.9% of AUM)
-
-
As of May 14, 2026, Erasca shares are valued at $10.37, up 716.5% over the past year, yielding an alpha of 689.24 percent compared to the S&P 500.
Company Overview
|
Metric |
Price |
|---|---|
|
Price (as of market close 2026-05-15) |
$10.23 |
|
Market capitalization |
$3.15 billion |
|
Total revenue (TTM) |
$277.02 million |
|
One-year price changes |
705.5% |
Company summary
-
It develops and advances therapies targeting RAS/MAPK pathway-driven cancers, with clinical lead candidates including ERAS-007 (an oral ERK1/2 inhibitor), ERAS-601 (an oral SHP2 inhibitor), and ERAS-801 (a CNS-penetrant EGFR inhibitor).
-
It operates as a clinical-stage biopharmaceutical company focused on the development and future commercialization of proprietary oncology therapeutics.
-
It targets patients with difficult-to-treat cancers such as non-small cell lung cancer, colorectal cancer, acute myeloid leukemia, and progressive glioblastoma multiforme.
Erasca, Inc. is a biotechnology company headquartered in San Diego, California, focused on discovering and developing cancer therapies driven by the RAS/MAPK pathway. The company operates a strong pipeline of oral targeted inhibitors, aimed at addressing important unmet medical needs in oncology. Its strategy focuses on the development of clinical candidates with different modes of action to establish a competitive edge in targeted cancer therapy.
What this transaction means for investors
Erasca’s new Acuta Capital position isn’t in the company’s top five, but it’s a significant bet. It was the seventh largest position out of 27 at the end of March.
Hopefully, Akuta Capital exited its position in April, before the stock crash. The stock has more than halved from its peak in April.
On April 27, the company reported the results of a phase 1 trial of ERAS-0015, a cancer treatment candidate it describes as a pan-RAS cell glue. The company’s experimental drugs are designed to block the RAS/MAPK pathway, which is involved in the spread of solid tumors.
Although the efficacy results were encouraging, the patient’s death led investors to question the future of ERAS-0015. It is one of two treatment candidates the company has in clinical phase testing.
The clock is ticking on Erasca. Without any products approved for sale, it has burned to $277 million in the last 12 months. At the end of March, the company had $408.5 million in cash and cash equivalents on its balance sheet.
Should you buy stock in Erasca right now?
Before buying stock in Erasca, consider the following:
I The Motley Fool Stock Advisor a team of analysts has just identified what they believe to be 10 best stocks for investors to buy now… and Erasca was not one of them. The 10 stocks that made the cut could produce huge gains in the coming years.
Think about when Netflix made this list on December 17, 2004… if you invested $1,000 during our recommendation, you will have $469,293!* Whenever Nvidia made this list on April 15, 2005… if you invested $1,000 during our recommendation, you will have $1,381,332!*
Now, it’s worth noting Stock Advisor’s the average total return is 993% – outperformed the market by 207% for the S&P 500. Don’t miss the latest top 10 list, available via Stock Advisorand join an investment community built by individual investors for individual investors.
See 10 stocks »
*The Stock Advisor returns as of May 16, 2026.
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a policy of disclosure.
Acuta Capital Bets on Erasca (ERAS) and Targeted Cancer Treatment With 354,575 Share Buy was first published by Motley Fool.
